海翔药业股价跌5.03%，南方基金旗下1只基金位居十大流通股东，持有1035.83万股浮亏损失321.11万元

Company Overview - Zhejiang Haixiang Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang Province, established on May 7, 1998, and listed on December 26, 2006 [1] - The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of the company includes: 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Stock Performance - On November 21, Haixiang Pharmaceutical's stock fell by 5.03%, trading at 5.85 yuan per share, with a transaction volume of 88.72 million yuan and a turnover rate of 0.92%, resulting in a total market capitalization of 9.469 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 3.2111 million yuan [2] Fund Management - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 16 days. The total asset size of the fund is 122.76 billion yuan [3] - During Cui Lei's tenure, the best fund return was 180.57%, while the worst return was -15.93% [3]